Transgene SA is a biotechnology company focused on the development of immunotherapies based on innovative viral vector technologies for the treatment of cancer and infectious diseases.
Business Segments
The company is strategically segmented into…
Analysis
Middle-of-the-road
Transgene SA sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
Valuation data is not available for this company.
Growth is moderate; the safety picture is stretched. The company scores 3/20 on our value-creation score: not creating value.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202671
4
2026
All-time high
71
Mar 2026
All-time low
4
Jun 2026
Average rank
38
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
17
—
—
—
Price/Earnings
55
—
—
—
Price/Book
50
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
27
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.